Selective lymph node dissection for castration-resistant prostate cancer

Urologia Internationalis

Volumn 88, Issue 4, 2012, Pages 441-446

  Busch, Jonas ^a   Hinz, Stefan ^a   Kempkensteffen, Carsten ^a   Erber, Barbara ^a   Klopf, Christian ^a   Weikert, Steffen ^a   Miller, Kurt ^a   Magheli, Ahmed ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biochemical recurrence; Lymph node dissection; PET CT imaging; Prostate cancer

Indexed keywords

DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; METASTASIS FREE SURVIVAL; METASTASIS RESECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATECTOMY; RECURRENT CANCER; TREATMENT INDICATION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BONE NEOPLASMS; CASTRATION; DRUG RESISTANCE, NEOPLASM; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862758827     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000335206     Document Type: Article

References (16)

1. Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA, Walsh PC, Trock BJ: The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol 2008; 179: 156-161.
2. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.
3. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850-1857.
4. Martorana G, Schiavina R, Franceschelli A: Should we perform imaging-guided lymph node dissection in patients with lymphatic recurrence of prostate cancer after radical prostatectomy? Eur Urol 2009; 55: 1302-1304.
5. Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E, Bertaccini A, Manferrari F, Castellucci P, Fanti S, Canini R, Grigioni WF, D'Errico Grigioni A: 11 Ccholine positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006; 176: 954-960.
6. 11C-choline positron emission tomography/ computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clin ical staging nomograms. Eur Urol 2008; 54: 392-401.
7. 11C-choline- positron emission/computed tomography- positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008; 102: 446-451.
8. 11C-choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer: preliminary results of a prospective study. Urol Int 2008; 81: 191-197.
9. Kohli M, Viswamitraa S, Schaefer R, Faas FH, Kumar U: Metastasectomy for isolated bilateral adrenal metastases in hormone-refractory prostate cancer. Clin Adv Hematol Oncol 2006; 4: 754-755.
10. NCCN: Systemic salvage therapy for castration- recurrent prostate cancer, 2010.
11. Graefen M: The modified Clavien system: A plea for a standardized reporting system for surgical complications. Eur Urol 2010; 57: 387-389.
12. Subramanian VS, Nguyen CT, Stephenson AJ, Klein EA: Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol Oncol 2008; 28: 504-509.
13. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M: The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187-196.
14. Heidenreich A, Thuer D, Polyakov S: Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis. Eur Urol 2008; 53: 260-272.
15. Capitanio U, Jeldres C, Perrotte P, Isbarn H, Crepel M, Cloutier V, Baillargeon-Gagne S, Shariat SF, Duclos A, Arjane P, Widmer H, Saad F, Montorsi F, Karakiewicz PI: Population- based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. Urology 2009; 74: 373-377.
16. Smith DC, Dunn RL, Strawderman MS, Pienta KJ: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998; 16: 1835-1843.